Zejing pharmaceutical: an advance loss of 372 million yuan to 455 million yuan in 2021

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Zhongji InnoLight Prices Hong Kong Listing at HK$980, Raising HK$53.41 Billion

Zhongji InnoLight Co., Ltd.（中际旭创股份有限公司）, a leading Chinese supplier of optical transceivers used in cloud and artificial-intelligence infrastructure, has priced its Hong Kong H-share offering at HK$980 per share, giving the base deal gross proceeds of HK$53.41 billion (US$6.81 billion).

Unpacking China | Key Chinese Firms to Watch This Week （19/07/2026-25/07/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Unpacking China | Key Chinese Firms to Watch This Week （05/07/2026-11/07/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.